PDSB PDS Biotechnology Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1472091 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY7.5%
TTM EPS YoY33.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-281.4%
ROA-121.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets27.3%
Debt / equity0.00x
Current ratio3.62x
Interest coverage-3.52x
Cash quality & payout
Operating cash flow / net income0.59x
Accruals ratio-49.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $19.03M | $22.57M | $27.76M | $29.43M | $11.25M |
| SG&A expense | $12.52M | $13.76M | $15.28M | $12.24M | $10.18M |
| Operating income | -$31.54M | -$36.32M | -$43.05M | -$41.67M | -$21.44M |
| Interest expense | $5.34M | $4.67M | $4.21M | $1.32M | $0 |
| Pretax income | -$35.67M | -$38.48M | -$44.35M | -$42.05M | -$21.43M |
| Income tax | -$1.17M | -$869,169 | -$1.41M | -$1.20M | -$4.52M |
| Net income | -$34.50M | -$37.61M | -$42.94M | -$40.85M | -$16.92M |
| EBITDA | -$31.52M | -$36.30M | -$43.03M | -$41.67M | -$21.43M |
| EPS (basic) | -0.74 | -1.03 | -1.39 | -1.43 | -0.66 |
| EPS (diluted) | -0.74 | -1.03 | -1.39 | -1.43 | -0.66 |
| Weighted avg. shares (diluted) | 46.38M | 36.45M | 30.95M | 28.60M | 25.60M |
| Balance sheet | |||||
| Cash & equivalents | $26.71M | $41.69M | $56.56M | $73.82M | $65.24M |
| Current assets | $28.25M | $45.05M | $59.06M | $76.48M | $66.84M |
| PP&E, net | $120,184 | $142,020 | $134,132 | $0 | $86 |
| Total assets | $30.49M | $45.36M | $59.39M | $77.01M | $67.20M |
| Current liabilities | $9.48M | $17.09M | $13.63M | $9.82M | $3.76M |
| Total liabilities | $21.24M | $26.35M | $33.26M | $33.01M | $3.99M |
| Shareholders' equity | $9.25M | $19.00M | $26.13M | $44.00M | $63.21M |
| Shares outstanding | 54.88M | 37.99M | 33.09M | 30.17M | 28.45M |
| Cash flow statement | |||||
| Operating cash flow | -$27.75M | -$35.03M | -$33.64M | -$25.71M | -$12.49M |
| Capital expenditure | $0 | $29,000 | $0 | — | — |
| Free cash flow | -$27.75M | -$35.06M | -$33.64M | — | — |
| Investing cash flow | $0 | -$29,000 | $0 | — | — |
| Financing cash flow | $12.77M | $20.19M | $16.38M | $34.29M | $48.89M |
| Depreciation & amortization | $21,836 | $21,112 | $17,359 | $86 | $5,357 |
| Stock-based compensation | $4.11M | $6.85M | $7.61M | $5.20M | $4.07M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.